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CaveolinTocotrienols (T3s) are members of the vitamin E family, have antioxidant properties, and are promising candi-
dates for neuroprotection in the pathogenesis of neurodegenerative disorders such as Parkinson's disease (PD).
However, whether their antioxidant capacities are required for their cytoprotective activity remains unclear. In
this regard, the antioxidant-independent cytoprotective activity of T3s has received considerable attention.
Here, we investigated the signaling pathways that are induced during T3-dependent cytoprotection of human
neuroblastoma SH-SY5Y cells, as these cells are used to model certain elements of PD. T3s were cytoprotective
against 1-methyl-4-phenylpyridinium ion (MPP+) and other PD-related toxicities. γT3 and δT3 treatments led
to marked activation of the PI3K/Akt signaling pathway. Furthermore, we identiﬁed estrogen receptor (ER) β
as an upstream mediator of PI3K/Akt signaling following γT3/δT3 stimulation. Highly puriﬁed γT3/δT3 bound
to ERβ directly in vitro, and knockdown of ERβ in SH-SY5Y cells abrogated both γT3/δT3-dependent
cytoprotection and Akt phosphorylation. Since membrane-bound ERβ was important for the signal-related
cytoprotective effects of γT3/δT3, we investigated receptor-mediated caveola formation as a candidate for the
early events of signal transduction. Knockdown of caveolin-1 and/or caveolin-2 prevented the cytoprotective ef-
fects ofγT3/δT3, but did not affect Akt phosphorylation. Thisﬁnding suggests that T3s and, in particular,γT3/δT3,
exhibit not only antioxidant effects but also a receptor signal-mediated protective action following ERβ/PI3K/Akt
signaling. Furthermore, receptor-mediated caveola formation is an important event during the early steps follow-
ing T3 treatment.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Vitamin E is a fat-soluble vitamin and is well known as an antioxi-
dant that is present in the cell membrane and protects cells and organs
against oxidative stress. There are 8 vitamin E derivatives:α-,β-,γ-, and
δ-tocopherol (αTOC,βTOC,γTOC, and δTOC, respectively) andα-,β-,γ-,
and δ-tocotrienol (αT3, βT3, γT3, and δT3, respectively) [1,2]. These
classes can be differentiated by an unsaturated side chain with three
double bonds in the farnesyl isoprenoid tail of TOCs and an isoprenoid
tail with 3 double bonds in T3s [1,2]. Furthermore, differences between
αT3, βT3, γT3, and δT3 are characterized by the number and location of
methyl groups on the chromanol ring. T3s are found only in a few veg-
etable fats such as palm oil and rice bran oil [3,4]. Numerous reports
have suggested that all types of vitamin E scavenge reactive oxygeniochemistry, Department of
versity Faculty of Medicine, 86
3; fax: +81 859 38 6150.
so).species and protect cells and organs against oxidative stress as their
common potent characteristic [5–7]. Furthermore, recent epidemiolog-
ical and clinical studies suggest that vitamin E is effective in oxidative
stress-related neurodegenerative disorders such as Parkinson's disease
(PD) [8–10], Alzheimer's disease [11], and amyotrophic lateral sclerosis
[12]. However, other clinical studies have failed to conﬁrm the efﬁcacy
of vitamin E members, especially αTOC, in the treatment of these dis-
eases [13–15]. Additionally, the detailed molecular mechanisms by
which vitamin E is neuroprotective have not been fully elucidated. Re-
cently, there has been signiﬁcant interest in the protective mechanisms
of vitamin E that are independent of its antioxidative properties; this in-
cludes its induction of receptor-mediated signal transduction [2].
PD is a neuropathological disorder involving the degeneration of do-
paminergic neurons in the substantia nigra, with the subsequent loss of
their terminals in the striatum [16]. The ensuing loss of dopamine
causes most of the debilitating motor disturbances associated with PD.
Although current PD medications treat the symptoms of the disease
without halting or retarding the degeneration of dopaminergic neurons,
there has been considerable interest recently in neuroprotection as a
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proposed as candidate neuroprotective agents for PD [19–21]. Oxidative
stress contributes, at least in part, to the pathogenic cascade leading to
dopaminergic neuronal degeneration in PD [16,19]. Therefore, antioxi-
dants are potential candidates for neuroprotective therapy against PD.
However, antioxidative therapy for PD using exogenous antioxidants
has not been successful in the clinical setting thus far [22]. A large-
scale study for the effects of a monoamine oxidase inhibitor (deprenyl)
and αTOC on the progression of early PD, referred to as the “DATATOP”
study, conﬁrmed the efﬁcacy of deprenyl but not of αTOC [20]. Howev-
er, interestingly, dietary epidemiological studies suggest that sufﬁcient
intake of vitamin E may prevent the onset of PD [8,9]. This ﬁnding sug-
gests that other non-oxidative cytoprotective effects of vitamin E in
addition to those provided by αTOC may be beneﬁcial for PD preven-
tion. In this sense, T3s may represent promising candidates for PD
prevention.
We previously reported that deprenyl and caffeine exhibit cyto- and
neuroprotective effects via PI3K-dependent signals in a cell model of PD
using SH-SY5Y cells [19,23]. These neuroprotective agents can interact
with several receptors on the plasma membrane and in doing so acti-
vate PI3K/Akt signaling [19]. Although T3s are known to activate PI3K/
Akt signaling in cerebral cortical neurons [24], direct target molecules
of T3s upstream of PI3K/Akt have not yet been identiﬁed. We hypothe-
sized that T3s also have cytoprotective effects against PD-related toxins,
and that this depends not only upon an antioxidative effect, but also
upon receptor-mediated signal transduction via PI3K/Akt-related sig-
nals. The aim of this study was to identify the target molecule of T3s
that mediates PI3K/Akt-dependent neuroprotection, and to clarify the
early steps of membrane trafﬁcking involved in the process.
2. Material and methods
2.1. Chemicals and antibodies
αT3, βT3, γT3, and δT3 were obtained from Eisai Food Chemical Inc.
(Japan, Tokyo). 1-Methyl-4-phenylpyridinium ion (MPP+), the adeno-
sine A2A receptor antagonist 8-(3-chlorostyryl) caffeine, and the D2 do-
pamine receptor antagonist droperidol were purchased from Sigma.
MG132 and the Trk neurotrophin receptor antagonist K252a were pur-
chased fromCalbiochem (La Jolla, CA, USA). All-trans-retinoic acid (RA),
thapsigargin, 3-(4,5-dimethylthiazol-2-yl) 2,5-diphenyl tetrasolium
bromide (MTT), the estrogen receptor antagonist tamoxifen, 17β-
estradiol (E2), and Hoechst 33342 were obtained from Wako (Osaka,
Japan). 2,4,6,7-3H (N)-Estradiol (3H-E2) was obtained from Perkin
Elmer Life and Analytical Sciences (Waltham,MA, USA). The PI3K inhib-
itor LY294002 and wortmannin were purchased from Alomone Labs
(Jerusalem, Israel). The Erk MAPK inhibitor PD98059, the p38MAPK in-
hibitor SB203580, and the JNK inhibitor SP600125were purchased from
Alexis (SanDiego, CA, USA). Full-length estrogen receptorsα (ERα) and
β (ERβ) were obtained from Invitrogen (Carlsbad, CA, USA). The follow-
ing antibodies were used in this study. Anti-phospho-Erk (E-4), anti-
Erk1 (K-23), anti-phospho-p38 (Tyr182-R), anti-p38 (H-147), anti-
phospho-JNK (Thr183/Tyr185-R), anti-JNK (D-2), anti-Akt1/2 (H-136),
anti-ERα (H226), anti-caveoline 1 (7C8), and anti-caveoline 3 (A-3)
were obtained from Santa Cruz Biotechnology. Anti-phospho-Akt
(Ser473), anti-β-actin, and anti-ERβwere purchased fromCell Signaling
Technology. Anti-caveoline 2 was purchased from EPITOMICS.
2.2. Cell culture and application of reagents
Human neuroblastoma cells SH-SY5Y were obtained from the ATCC.
Basal culture conditions for SH-SY5Y have been described previously
[19]. Brieﬂy, SH-SY5Y cells were maintained at 37 °C in 5% CO2 in
DMEM/F12 medium with or without phenol red, supplemented with
5% fetal bovine serum, 10,000U/ml penicillin G, and 100 mg/ml strepto-
mycin. Culture medium was exchanged twice a week during cellgrowth. Experiments were performed using 5 × 105 cells per well in
6-well culture plates for immunoblots, 1 × 103 cells per well in 8-well
chamber slides for immunohistochemistry, and 3 × 103 cells per well
in 96-well culture plates for viability assays. Cells were differentiated
into neural lineages by incubation for 2–3 days with 5 μM RA. PD-
related toxins (MPP+, MG132, and thapsigargin) and T3s were added
to themedium simultaneously and incubated for the duration indicated
in the ﬁgure legends. Kinase inhibitors or receptor antagonists were
added to the medium at 1 h or 30 min, respectively, before treatment
with T3s. To transfect the Akt-PH vector (gifted by Dr. Ohno) [25] into
SH-SY5Y cells, TransFast™ Transfection Reagents (Promega, Madison,
WI, USA) were used in accordance with the manufacturer's protocol.
2.3. Cell viability assay (MTT assay)
Cell viabilitywasmeasured using theMTT assay following the proto-
col described previously with some modiﬁcations [19]. Speciﬁcally, 3
× 103 cells/well were seeded in 96-well plates, cultured for 2 or 3 days
with RA, and then toxins and T3s were added to the culture medium.
After 48 h, cells were incubated with MTT for 2 h at 37 °C. After adding
100 μl of 0.04NHCl in 2-propanol andmixing thoroughly to dissolve the
dark blue crystals, the MTT reduction was measured with a microplate
reader (Bio-Rad; wavelength of 570 nm). Data are presented as percent
post-treatment recovery (percent live cells), where the absorbance
from the control non-treated cells was deﬁned as 100% live cells.
2.4. Immunobloting and immunoﬂuorescent staining
For immunoblots, cultured cells were harvested from 6-well culture
plates, and lysed in SDS sample buffer (50mM Tris–HCl, pH 6.8, 2% SDS,
10% glycerol, 1 mM phenylmethylsulfonyl ﬂuoride, and 2 mM EDTA).
Aliquots (20 μg) were separated on the basis of molecular size on
7.5–12%polyacrylamide gels, transferred onto polyvinylidene diﬂuoride
membranes (Hybond-P; GE Healthcare, Buckinghamshire, UK), and hy-
bridized with the required antibody in PBS-Tween 20 at room temper-
ature (RT) for 1 h. The immunoreactive signal was detected using
horseradish peroxidase-linked anti-rabbit IgG and ECL detection re-
agents (GE Healthcare). Protein content of each sample was measured
using the BCA protein assay system (Thermo Fisher Scientiﬁc Inc.,
Rockford, IL, USA). The density of immunoblot signal (expressed as
the ratio of phosphorylated/total protein for Akt, Erk, p38 and JNK)
was semi-quantiﬁed using Image J software.
For immunoﬂuorescent staining, 4% paraformaldehyde-ﬁxed SY-
SY5Y cells were washed with PBS, and incubated with ice-cold solution
containing 95% ethyl alcohol and 1% acetic acid for 5min. After washing
with PBS twice, cells were incubated with antibodies overnight at 4 °C.
Then, cells were washed twice with PBS and incubated with a Texas
Red-conjugated secondary antibody at RT for 4 h. Cells were washed
with PBS several times and ﬁnally covered using Vectashield (Vector
Lab Inc., Burlingame). Nuclei were stained using Hoechst 33342. Immu-
nohistochemical signals were detected using ﬂuorescent microscopy.
2.5. Binding analysis between T3s and ER
To analyze binding between T3s and ERα or ERβ, competitive radio-
metric binding assays [26]were carried out. Full-length ERα or ERβ pro-
tein (0,5 nM) and 3H-E2 (1 nM) were incubated in 500 μl of binding
buffer (10 mM Tris–HCl, pH 7.4, 1.5 mM EDTA, 1 mM dithiothreitol,
10% glycerol, and 1% bovine serum albumin) with 10−9–10−4 M T3s
or 10−12–10−6 M E2 at 30 °C for 1 h. After incubation, the reaction
was terminated by adding 200 μl of activated charcoal suspension.
After 1 h of absorption, ER-bound 3H-E2 and unbound 3H-E2 (absorbed
by the charcoal) were separated by centrifugation for 3 min at 1000 ×g.
Aliquots (500 μl) of the supernatant containing ERα/ERβwere trans-
ferred to another tube, and 3 ml of scintillation cocktail (Perkin Elmer)
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2.6. Gene silencing
Gene silencing of ERα, ERβ, caveolin-1, caveolin-2, and caveolin-3
was performed by RNA interference. The siRNA sequences for ERα and
ERβ were designed in accordance with a previous report [27] and
purchased from Sigma Genosys. Control siRNA, caveolin-1 siRNA,
caveolin-2 siRNA, and caveolin-3 siRNA were purchased from Santa
Cruz (Santa Cruz, CA, USA). Transfection of siRNAs was performed
using the siRNA Reagent System (Santa Cruz) in accordance with the
manufacturer's protocol.
2.7. Antibody array
Cell lysates were prepared as recommended by Kinexus Bioinfor-
matics Corporation (Vancouver, BC, Canada). Protein extracts from
SH-SY5Y cells treatedwithγT3 (1 μM, 2 h) or the vehiclewere collected,
and their protein proﬁles were compared using the Kinexus™ antibody
array system following the manufacturer's protocol.
2.8. Statistical analyses
Quantitative data were assessed by ANOVA using the Stat View soft-
ware. The criterion for statistical signiﬁcancewas p b 0.01 for the cell vi-
ability assay, and p b 0.05 for semi-quantitative data obtained from
immunoblotting. All values are expressed as means ± S.E.
3. Results
3.1. T3s exhibit a cytoprotective effect against PD-related toxicities
In order to clarify the cytoprotective effect of T3s against PD-related
toxicities,we established cell toxicitymodels of PD using the human do-
paminergic neuroblastoma cell line, SH-SY5Y. Although the mitochon-
drial toxin MPP+ (2 mM) reduced cell viability to around 40% at 48 h
after treatment, simultaneous treatment with T3s signiﬁcantly in-
creased viability in a dose-dependent manner (Fig. 1A–D). The protec-
tive effects of γT3 (Fig. 1C) and δT3 (Fig. 1D) were more remarkable
than those of αT3 and βT3 (Fig. 1A, B). We also investigated the effect
of simultaneous T3 treatment (1 μM) against cell death induced by the
proteasome inhibitor MG132 (5 μM) (Fig. 1E) or the endoplasmic retic-
ulum stressor thapsigargin (1 μM) (Fig. 1F). Treatment with αT3, βT3,
γT3, or δT3 reduced the amount of cell death induced by a 48-h expo-
sure to MG132 (Fig. 1E). The cytoprotective effects of γT3 and δT3
were superior to those of αT3 and βT3, as well as the protective effect
against MPP+ (Fig. 1A–D). Similarly, the cytoprotective effects of γT3
and δT3 against thapsigargin were signiﬁcant; however, those of αT3
and βT3 were mild and were not statistically signiﬁcant (Fig. 1E).
To conﬁrmwhether these cytoprotective effects were dependent on
the antioxidative action of T3s, we measured lipid hydroperoxide and
protein carbonyl as indices of oxidative stress. Although each T3 showed
a tendency to reduce the production of lipid hydroperoxide induced by
MPP+ exposure, this antioxidative effect was not statistically signiﬁcant
(Supplementary Fig. 1A). Statistical differences in the level of protein
carbonyl when compared with and without T3 treatment were not ob-
served with regard to MPP+-induced toxicity (Supplementary Fig. 1B).
Since the cytoprotective effects of γT3 and δT3 were superior to those
of the other T3s, the subsequent experiments were performed using
mainly these two compounds.
3.2. γT3 and δT3 activate PI3K/Akt signaling in SH-SY5Y cells
Although vitamin E is an established antioxidative agent, the T3s
were cytoprotective against agents with oxidative stress-independenttoxicities, including a proteasome inhibitor and an activator of endo-
plasmic reticulum stress, as shown in Fig. 1. Therefore, we hypothesized
that the cytoprotective effect of T3s is, at least in part, also dependent on
intracellular signal transduction. In order to elucidate which signaling
pathways might be involved, we investigated the activation of
the MAPK and PI3K/Akt pathways as candidate signals for the
cytoprotective action of T3s. As seen in Fig. 2, Akt was phosphorylated
at 120 min after T3 treatment, particularly in response to γT3 and
δT3 (Fig. 2A–D). We also assessed the phosphorylation of Erk1/2
(Fig. 2E–H), p38 (Fig. 2I–L), and JNK (Fig. 2M–P). Erk1/2was signiﬁcant-
ly phosphorylated upon γT3 and δT3 treatments, but not by αT3 and
βT3 (Fig. 2E–H). Two other MAPKs, p38 and JNK, were not signiﬁcantly
phosphorylated by treatment with T3s under our experimental condi-
tions (Fig. 2I–P).
We examined the translocation of Akt using PH-Akt–GFP-expressing
cells because translocation of Akt to the proximity of the plasma mem-
brane from the cytosolic area is a robust index of Akt activation. Treat-
ment of γT3 and δT3 induced translocation of PH-Akt–GFP from the
cytoplasm to the plasma membrane area (Fig. 2Q–S), suggesting that
γT3 and δT3 can activate the Akt/PI3K signaling pathway.
Based on these results, we examined whether a panel of kinase in-
hibitors could inhibit the cytoprotective effects of γT3 and δT3. Neither
PD98059 (5 μM)nor SB203580 (5 μM) (inhibitors of Erk1/2 and p38, re-
spectively) reversed the cytoprotective effects of γT3 (Fig. 2T) and δT3
(Fig. 2U). However, strikingly, the PI3K inhibitors LY29004 (10 μM)
and wortmannin (2 μM) dramatically blocked γT3-dependent protec-
tion. The JNK inhibitor SP600125 (5 μM) also showed an inhibitory ef-
fect (Fig. 2T, U), which we attribute to suppression of the mechanism
by which MPP+ itself triggers toxicity.
3.3. Estrogen receptorβ plays an important role in the cytoprotective effects
of γT3 and δT3
In neuronal cells, several receptors, including Trk neurotrophin re-
ceptors, dopamine receptors, adenosine receptors, and ERs, have been
reported as upstreammediators of PI3K/Akt signaling. Therefore, we in-
vestigated the association of several receptors with T3-related
cytoprotection using chemical inhibitors. The dopamine D2 receptor
antagonist droperidol (10 μM), the neurotrophin receptor (Trk) inhibi-
tor K252a (3 nM), and the adenosine A2A receptor antagonist 8-
(chlorostyryl) caffeine (10 μM) did not inhibit the cytoprotective effects
ofγT3 and δT3 againstMPP+ toxicity (Fig. 3A, B). On the other hand, the
ER antagonist tamoxifen (1 μM) inhibited the cytoprotective effects of
both γT3 and δT3 (Fig. 3A, B).
The tamoxifen-dependent inhibition of γT3 and δT3 activities indi-
cates that ER signaling is associated with their cytoprotective effects.
Since docking simulation has previously shown that δT3 can bind to
ERβ, we measured binding activity between T3s and ERα/ERβ using a
radiometric competitive inhibition method [26] (Fig. 4). This showed
direct binding of γT3 and δT3 to ERβ, with the latter interaction being
more pronounced. On the other hand, the binding activities of αT3
and βT3 to ERβ or of αT3, βT3, γT3, δT3 to ERαwere weak (Fig. 4). Al-
though all T3s have a common farnesyl isoprenoid tail, the structure of
the chromanol ring differs between individual members. We thus infer
that the different ERβ-binding activities exhibited by T3s may depend
on the number and location of methyl groups on the chromanol ring.
We next investigated the translocation of ERβ under γT3 and δT3
treatments. In SH-SY5Y cells, ERβ localized mainly in extranuclear
spaces such as the cytoplasm and plasma membrane. Treatment with
γT3 or δT3 induced the translocation of ERβ from cytosolic and/ormem-
brane areas to the perinuclear space (Supplementary Fig. 2). These re-
sults suggest that γT3 or δT3 also binds to ERβ in SH-SY5Y cells and
that ERβ-related signalingmay play an important role in cytoprotection.
To clarify whether the cytoprotective effect of γT3 and δT3 is due to
ERβ speciﬁcally, rather than ERα, we performed gene silencing of ERα
and ERβ by RNA interference (Fig. 5A). Knockdown of ERβ prevented
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Fig. 1. T3s exhibit a cytoprotective effect against PD-related toxicities in SH-SY5Y cells. (A–D) T3s are cytoprotective against MPP+ (2 mM) in a dose-dependent manner. T3s and MPP+
were added simultaneously, and viabilities were measured at 48 h after treatment using theMTT assay. a: p b 0.001 vsMPP+(−)/T3s(−), b: p b 0.01 vsMPP+ only, c: p b 0.001 vsMPP+
only (ANOVA). (A, B) αT3 and βT3 are mildly protective against MPP+. (C) γT3 and δT3 are strongly protective against MPP+. (E) T3s are cytoprotective against the
proteasome inhibitor MG132 (5 μM). T3s (1 μM) and MG132 were added simultaneously, and viabilities were measured at 48 h after treatment, by using the MTT assay. a: p b 0.001
vs MG132(−)/T3s(−), b: p b 0.01 vs MG132 only, c: p b 0.001 vs MG132 only (ANOVA). (F) T3s are cytoprotective against the endoplasmic reticulum stressor thapsigargin (Thap) (1 μM).
T3s (1 μM) and Thapwere added simultaneously, and viabilitywasmeasured at 48 h after treatment using theMTT assay. a: p b 0.001 vs Thap (−)/T3s(−), b: p b 0.01 vs Thap only (ANOVA).
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down of ERα showed no inhibitory effect against γT3 and had only
mild effects against δT3 (Fig. 5B, C). The partial effects of ERα knock-
down may be attributable to the fact that ERα homodimerizes or
heterodimerizes with ERβ on the cell membrane. We also investigatedthe inhibitory effect of ERβ knockdown on the phosphorylation of Akt.
ERβ knockdown signiﬁcantly inhibited the γT3 or δT3-induced phos-
phorylation of Akt (Fig. 5D, E).
ER signaling includes genomic (i.e., modulation of gene expression)
and non-genomic pathways. We ﬁrst examined the ER-dependent
Fig. 2. T3s, especially γT3 and δT3, activate the PI3K/Akt pathway. Semi-quantitative data of the pAkt/Akt blots (A–D), pErk/Erk (E–H), p-p38/p38 (I–L), and pJNK/JNK (M–P). Cell extracts
were collected several minutes after αT3 (1 μM) (A, E, I, M), βT3 (1 μM) (B, F, J, N), γT3 (1 μM) (C, G, K, O), or δT3 (1 μM) (D, H, L, P) treatment. β, g (D, H, L) treatment leads to Akt phos-
phorylation after 120min. a: p b 0.05 vs 0min (ANOVA) (B, C, D). Erk is phosphorylated by gT3 or dT3 (G, H). a: p b 0.05 vs 0min, b: p b 0.01 vs 0min (ANOVA). TheGFP-fused PHdomain
of Akt was translocated from the cytoplasm to the plasmamembrane (Q–S). Scale bar= 10 μm. (Q) PH-Akt–GFPwas located in the cytosolic area in untreated cells (CTL), (R) PH-Akt–GFP
was translocated to the plasmamembrane at 90min after treatment with γT3 (1 μM), and (S) PH-Akt–GFPwas translocated to the plasmamembrane at 90 min after treatment with δT3
(1 μM).(T, U) Kinase-inhibitor experiments. PD: Erk inhibitor PD98059, SB: p38 inhibitor SB203580 (10 μM), SP: JNK inhibitor SP600125 (10 μM),Wo and LY: PI3K inhibitor wortmannin
(2 μM) and LY294002 (10 μM), respectively. Each inhibitor was added to the culturemediumat 30min beforeMPP+ (2mM) and T3s (1 μM). a: p b 0.001 vsMPP+(−)/T3s(−), b: p b 0.01
vsMPP+ only, c: p b 0.001 vsMPP+/T3s (ANOVA). (T) The PI3K inhibitorsWo and LY prevented the cytoprotective effect ofγT3 againstMPP+ toxicity. The JNK inhibitor SP also prevented
the cytoprotective effect of γT3. (U) The PI3K inhibitors Wo and LY prevented the cytoprotective effect of δT3 against MPP+ toxicity, as did the JNK inhibitor SP.
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Fig. 3. Tamoxifen, an ER inhibitor, prevents the cytoprotective effect of γT3 and δT3. The ER inhibitor tamoxifen (Tamo, 1 μM), but not the dopamine D2 receptor antagonist droperidol
(Drop), Trk neurotrophin receptor antagonist K252a (3 nM), or the adenosine A2A receptor antagonist 8-(chlorostyryl) caffeine (Caff, 10 μM), abrogated the cytoprotective effect
of γT3 (A) and δT3 (B) in SH-SY5Y cells treated with MPP+. Viability was measured at 48 h after MPP+ and T3 treatment. a: p b 0.001 vs MPP+(−)/T3s(−), b: p b 0.001 vs MPP+
only, c: p b 0.001 vs MPP+/T3s (ANOVA).
Fig. 4. Competitive radiometric binding assay for T3s to ERα and ERβ. (A) Competitive radiometric binding of free E2 to ERα. (B) Competitive radiometric binding of free E2 to ERβ. (C–F)
Competitive radiometric binding of T3s to ERα. Data show weak binding between T3s and ERα. (G–J) Competitive radiometric binding of T3s to ERβ. γT3 (I) and δT3 (J) competitively
inhibit binding between ERβ and 3H-E2 in a ligand concentration-dependent manner, suggesting that both γT3 (I) and δT3 (J) can bind to ERβ.
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Fig. 5. ERβ is a key molecule in the γT3 or δT3-related cytoprotection mechanism against
MPP+ in SH-SY5Y cells. (A) Gene silencing of ERα and ERβ using siRNA. (B) Gene silencing
of ERβ abrogated the cytoprotective effect of γT3 in cells treated with MPP+. a: p b 0.001
vs MPP+(−)/γT3(−), b: p b 0.001 vs MPP+ only, c: p b 0.001 vs MPP+/γT3/CTL siRNA.
(C) Gene silencing of ERβ abrogated the cytoprotective effect of δT3 in cells treated with
MPP+. a: p b 0.001 vs MPP+(−)/δT3(−), b: p b 0.001 vs MPP+ only, c: p b 0.001 vs
MPP+/δT3/CTL siRNA. (D)Gene silencing of ERβ prevented the phosphorylation of Akt fol-
lowing γT3 treatment. a: p b 0.05 vs no treatment, b: p b 0.05 vs γT3 treatment. (E) Gene
silencing of ERβ prevented the phosphorylation of Akt upon δT3 treatment. a: p b 0.05 vs
no treatment, b: p b 0.05 vs δT3 treatment.
Table 1
The list of upregulated protein (z-ratio N 1.2) from antibody microarray screening
(Kinexus™ antibody array).
Molecule Antibody Character
ATF2 Pan-speciﬁc Activating transcription factor 2 (CRE-BP1)
Coﬁlin 1 Pan-speciﬁc Actin modulating protein, endocytosis a
Caveolin 2 Pan-speciﬁc Caveolae-related protein a
Aurora A Pan-speciﬁc Aurora kinase, stabilization of microtubulas,
regulator of mitotic call division
a
CREB1 S133 cAMP response element binding protein
CDK5 Pan-speciﬁc Cyclin-dependent protein kinase, regulator
of endocytosis
a
COT Pan-speciﬁc Osaka thyroid oncogene protein-serine kinase (Tpl2)
elF4E S20S Eukaryotic translation initiation factor 4
Erkl/2 T202 + Y204 Extracellular regulated protein-serine kinase 1 + 2
a Endocytosis-related and/or actin/microtubules-related protein.
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tional targets, cathepsin D and Egr-1. In HeLa cells, E2, γT3, and δT3 up-
regulated both transcripts; however this was not observed in SH-SY5Y
cells (Supplementary Fig. 3). These results suggest that, at least in SH-
SY5Y cells, ERβmay signal via the non-genomic pathway upon activa-
tion by T3s.
It has been reported that phenol red can bind to ERs, and in doing so
exhibit estrogenic effects [28]. However, the protective effect of γT3
and δT3 was similar in phenol red-free medium and regular medium
(Supplementary Fig. 4). Therefore, regular medium was used in all
experiments.
3.4. Caveola formation is important for the cytoprotective effect of γT3 and
δT3
In order to characterize the immediate signaling events triggered by
T3 treatment, we utilized a Kinexus™ antibody array. Molecules
that had a high z-ratio (z-ratio N 1.2) and were upregulated by
γT3 treatment (1 μM, 2 h) in SH-SY5Y cells are listed in Table 1. Interest-
ingly, 4 of the top 9 molecules were classiﬁed as endocytosis-related oractin/microtubule modifying-related molecules. This ﬁnding suggests
that γT3/ERβ signaling may involve endocytotic action, such as caveola
formation, as an early step.
Receptors on the plasma membrane are usually localized in lipid
rafts. The binding of extracellular ligands to receptors triggers the for-
mation of caveolae, which are vesicular structures involving scaffolded
membrane domains. Transport in caveolae ensures that extracellular
signals are transported to intracellular organelles for degradation or
recycling to the surface. It has been reported that the ER is foundwithin
caveolae at the plasmamembrane, and caveolae are believed to link es-
trogen uptake to the non-genomic activities of ERs [29]. Therefore, we
hypothesized that T3/ERβ-mediated signaling may involve caveola for-
mation. We investigated whether knockdown of caveolin, an integral
component of caveolae, inhibited the cytoprotective effects and Akt
phosphorylation in response to T3 treatment. Knockdown of caveolin-
1 (Fig. 6A) and caveolin-2 (Fig. 6B), prevented the cytoprotective effects
of γT3 and δT3 (Fig. 6C, D). Interestingly, caveolin knockdown did not
inhibit the Akt phosphorylation induced by γT3 and δT3 treatments,
suggesting that the activation of PI3K/Aktmay be anupstreammediator
of caveola formation. Knockdown of caveolin-3, which is generally a
muscle-speciﬁc isoform, also prevented the cytoprotective effect of
T3s, and did not inhibit Akt phosphorylation (Supplementary Fig. 5).
4. Discussion
The protective effect of T3s in neurodegenerative diseasemodels has
received considerable attention [4,24]. Since vitamin E is well known
as an antioxidant, many previous studies have suggested that the pro-
tective effect of T3s depends upon their antioxidative effects in neuro-
blastoma cell lines [30,31]. However, there is evidence that other
cytoprotective mechanisms of T3s involving intracellular signal cas-
cades may be at play in neurodegenerative disease models [24]. There-
fore in this study, we focused upon antioxidant-independent
cytoprotective effects of T3 and investigated the detailed mechanisms
of T3-induced cytoprotection using a cellular model of PD. It has been
reported that SH-SY5Y cells differentiated by 10 μM RA plus 1% FBS for
7 days is suitable for studying PD [32]. However, we used SH-SY5Y
cells differentiated by 5 μM RA and 5% FBS for a short period
(2–3 days), because an effect of RA-associated PI3K activation should
be reduced.
Recently, neuroprotection has been proposed as a therapeutic strat-
egy for the treatment of PD [17–19]. Oxidative stress contributes, at
least in part, to the pathogenic cascade leading to dopaminergic neuro-
nal degeneration in PD. Since αTOC, the most common derivative of
vitamin E, is well known as an antioxidant, it represents a promising
candidate as a therapeutic agent for PD [8,9]. Moreover, some epidemi-
ologic studies suggest that sufﬁcient intake of vitamin E is protective
against the onset of PD. However, antioxidative therapy for PD using ex-
ogenous antioxidants, including αTOC, has not been successful thus far
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Fig. 6. Caveola formation, including that of caveolin protein, is important in the cytoprotective effects ofγT3 and δT3. (A) Gene silencing of caveolin-1 via speciﬁc siRNA. (B) Gene silencing
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other vitamin E family members, namely the T3s.
In this study, γT3 and δT3 were particularly effective in their protec-
tion against PD-related toxicities. T3s did have mild antioxidative ef-
fects, as shown in Supplementary Fig. 1. However, it is difﬁcult to
conclude whether this contributes to their cytoprotective activity
for the following reasons: (i) the antioxidative effect of T3 was not sta-
tistically signiﬁcant in the MPP+ treatment model (Supplementary
Fig. 1A, B) and (ii) T3s also protected against the proteasome inhibitor
MG132 and the endoplasmic reticulum stressor thapsigargin, neither
of which are directly associated with induction of oxidative stress
(Fig. 1B, C). These observations suggest that T3s, and in particular γT3
and δT3, exert both antioxidant-dependent and -independent effects.
Since the PI3K/Akt and the MAPK pathways play an important
role in neuroprotection [19,23,24,33], we investigated these signaltransduction systems as candidates in our model. Akt was signiﬁcantly
phosphorylated at 120min after γT3 and δT3 treatments, and PI3K inhi-
bition dramatically reduced the cytoprotective effects of γT3 and δT3
(Fig. 2), suggesting that activation of PI3K/Akt is a key signal for the
cytoprotective effects ofγT3 and δT3. Erkwas alsomildly phosphorylat-
ed upon γT3 or δT3 treatment, but this effect was less robust than that
observed for Akt; additionally, the Erk inhibitor did not reduce T3-
dependent cytoprotection (Fig. 2). The JNK inhibitor SP600125 also an-
tagonized γT3/δT3-mediated cytoprotection (Fig. 2). We consider that
this was related more to suppression of the mechanism by which
MPP+ is usually converted to a toxic molecule, rather than to blockade
of T3-dependent signaling per se.
We also attempted to identify factors acting upstream of PI3K/Akt
signaling. From previous reports, several receptor-related signals have
been identiﬁed, such as the Trk neurotrophin receptor [19,34,35],
Fig. 7. Schematic diagramof the T3-dependent cytoprotective signaling pathway. T3s bind
to ERb directly, and this ERβ signal then induces activation of the PI3K/Akt pathway,which
triggers caveola formation involving ERβ. These initial events constitute an estrogen-
dependent non-genomic pathway that is cytoprotective.
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insulin receptor [39]. In this study, we targeted the Trk receptor, A2A re-
ceptor, D2 receptor, and ERs as potential factors upstream of PI3K/Akt
since they are reported to be important for neuroprotection. Interest-
ingly, the ER antagonist tamoxifen inhibited the cytoprotective effects
of γT3 and δT3 (Fig. 3), suggesting that the ER may be an initial target
for these T3s. Therefore, we tried to identify which isoform of ER, ERα
or ERβ, was more critical for the effect of these tocotrienols. An ER/T3
binding assay showed that the most prominent interactions were be-
tween γT3 and δT3 and ERβ However, this binding was much weaker
when compared to that between ERβ and its natural ligand, E2, as
shown by the high concentrations of T3s required to detect interaction.
Recently, using a software-based approach, Comitato et al., reported
that δT3 can bind ERβ and that the 5-hydroxyl group on the chromanol
ring of δT3 is important for direct binding [26]. Our T3s are highly puri-
ﬁed when compared to those described in previous reports, and by
comparing several types of T3, we found that δT3 and γT3 can bind to
ERβ (Fig. 4). Considering the structures of T3, we suggest that that the
differences in binding activity of the T3 family members to ERβ are
due to variations in the number and location of methyl groups on
the chromanol ring. We hypothesize that T3 members with lower
number of methyl groups located on the chromanol ring and around
the 5-hydroxyl group are more likely to bind tightly to ERβ.
Moreover, we investigated the functional interaction between γT3/
δT3 and ERβ using siRNA. Knockdown of ERβ clearly prevented the
cytoprotective effects of γT3 and δT3, whereas ERα knockdown mod-
estly inhibited the cytoprotective effect of δT3 (Fig. 5C).We hypothesize
that the inhibitory effect of ERα knockdown is indirectly due to the ef-
fect of ERβ, since ERα and ERβ can heterodimerize with each other on
the plasma membrane [40].
Interestingly, although the binding between ERβ and δT3 showed
higher afﬁnity than that between ERβ and γT3, the cytoprotective ef-
fects of both compounds were almost identical. This discrepancy may
be due to slight differences in their mechanisms of action. For example,
γT3 was a more robust activator of Akt and was also a more potent re-
ducer of lipid hydroperoxide when compared with other T3s. The
cytoprotective mechanisms of γT3 may extend beyond its ERβ-related
activity.
Upon stimulation of ERα and ERβ by estrogen, the receptors translo-
cate to the nucleus and act as transcription factors thatmodify the activ-
ity of target genes [38,41]. In addition to this conventional activity,
estrogen also utilizes plasma membrane ERs, and thus the two path-
ways are often referred to as “classic genomic” and “non-genomic”
pathways [38]. The classical genomic activity of ERs generally requires
prolonged estrogen exposure [42]. On the other hand, the non-
genomic action of estrogen on membrane-associated ERs is rapid and
leads to the activation of membrane-associated signaling molecules,
such as PI3K and MAPKs [38,43]. Membrane localization of ERs in SH-
SY5Y cells [44] and several other cell types [45,46] has been reported
previously. Furthermore, it has been reported that S-palmitoylation
is important for ER localization at the plasma membrane [47]. In order
to conﬁrm which pathway was predominant in the cytoprotective
role of T3s in SH-SY5Y cells, we examined the induction of the
genetic pathway-related molecules, cathepsin D and Egr-1, under γT3
or δT3-treated conditions. Since neither molecule was induced
by T3s in SH-SY5Y cells, we suggest that the protective effect of T3 in
SH-SY5Y cells may depend on non-genomic, rather than genomic,
pathways.
In order to characterize the events proximal to T3 treatment, we car-
ried out differential screenings for proteins using a Kinexus™ antibody
array. This analysis showed that, of the top 9 molecules, 4 were classi-
ﬁed as endocytosis-related (e.g., coﬁlin 1, caveolin-2, CDK5) or as mod-
iﬁers of actins or microtubules (e.g. coﬁlin 1, Aurora A). Therefore, we
hypothesized that the T3/ER signal may involve endocytotic action,
such as caveola formation, as an early step. Indeed, recent reports sug-
gest that the non-genomic actions of ER are linked to caveola formation[29]. Caveolae are one of the factors that can induce receptor-mediated
endocytosis [46,48]. Caveolae are present in the plasma membrane of
most cell types and are thought to form membrane macrodomains or
lipid rafts. The major structural protein of caveolae are caveolins [46],
which are a family of unusual integral membrane proteins that each in-
sert a hydrophobic loop into the membrane from the cytosolic side but
do not extend across the plasmamembrane. In order to conﬁrm that ca-
veolae are associated with T3/ER signaling we silenced caveolin-1,
caveolin-2 (Fig. 6), and caveolin-3 (Supplementary Fig. 5). Under our
experimental conditions, caveolin knockdown dramatically reduced
the cytoprotective effects of γT3 and δT3. However, phosphorylation
of Akt was not prevented by caveolin knockdown, suggesting that
γT3/δT3 activation of Akt may occur prior to caveola formation.
Oxidative stress contributes to the pathogenic cascade leading to do-
paminergic neuronal death in PD [49]. Furthermore, mitochondrial dis-
turbance, which induces the generation of reactive oxygen species and
causes secondary oxidative stress, is also important in the pathogenesis
of PD [16,50]. However, antioxidative therapy against PD has not proved
successful thus far. Becausemost antioxidants have very short half-lives,
it has been difﬁcult to achieve a prolonged effect during the long-term
progression of neurodegenerative diseases such as PD. Neuroprotective
drugs and food ingredients that are not associated with antioxidant
properties should also be considered as treatments to delay the onset
or progression of PD. Although T3s have an antioxidative effect, other
cytoprotective mechanisms of T3s should be considered. In this study,
we have therefore clariﬁed the cytoprotective effects of T3s, and in par-
ticular those of γT3 and δT3. In summary (Fig. 7), γT3/δT3 binds to ERβ,
which then forms a homodimer of ERβ or a heterodimer with ERα, on
the plasma membrane, leading to activation of PI3K/Akt signaling.
These events may trigger caveola formation via receptor-mediated en-
docytosis. After this early event, a non-genomic pathway causes ER up-
regulation (Fig. 7). Since ERβ is expressed not only in SH-SY5Y cells but
also in the dopaminergic neurons of the substantia nigra of the mouse
brain (our unpublished observations), these intracellular signals may
also be activated by T3 administration in the PD brain.
1312 K. Nakaso et al. / Biochimica et Biophysica Acta 1842 (2014) 1303–1312Our data have demonstrated a novel cytoprotectivemechanism that
is employed by the tocotrienols γT3 and δT3 and includes membrane
ERβ/PI3K/Akt signaling via caveola formation, and this effect is not de-
pendent on the antioxidative effect of T3s. This ﬁnding suggests that
the ERβ/PI3K/Akt pathway may be a promising candidate for novel
PD-targeted therapeutic agents.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbadis.2014.04.008.
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